

Breast Cancer Factsheet: Insights & Key Developments

Key Insights on Breast Cancer Care and Infrastructure

Core Pillars:

- 1. Infrastructure
- 2. Treatment Access, Research Funding and Awareness Campaigns
- 3. Survival Rates, Early Detection and Palliative Care
- 4. Utilization of Biomarkers
- 5. Clinical Guidelines
- 6. Reimbursement
- 7. Breast Cancer Screening

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping breast cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Breast cancer incidence: Approximately 33% of all female cancers.
- Incidence rate: Approximately 117.5 per 100,000 women per year.
- Total cases (2020): Approximately 58,500 new cases reported.
- · Lifetime risk in France: Approximately 1 in 8 women.
- Breast cancer deaths (2020): Approximately 12,100 deaths.
- 5-year survival rate: Approximately 88%.
- Most affected age group: The average age at diagnosis is 63 years old.
- Screening participation (ages 50-74): Approximately 47.8% of women participate in breast cancer screening programs.



Infrastructure

Strengths

- Advanced cancer centers (e.g., Gustave Roussy, Institut Curie) with nationwide access to HER2/ER/PR/BRCA/NGS testing.
- National programs like INCa and the Genomic Medicine Plan 2025 support molecular testing and personalized care.

Opportunity


- Scale genomic services across all regions under the national cancer plan.
- Strengthen referral systems to top-tier centers for complex cases.


Weakness

- Regional disparities in infrastructure, especially between urban and rural areas.
- Higher-level molecular diagnostics less accessible in smaller hospitals.

Threats

- Infrastructure imbalances may delay access to advanced diagnostics in rural settings.
- Capacity challenges with rising demand for personalized testing.





Moderate infrastructure, primarily in private settings or research institutions.


2. Limited infrastructure, available only in select centers or for high-cost private testing.

 Minimal or no infrastructure, testing mostly unavailable or sent abroad.

South Africa Kenya Nigeria Kenya Egypt Kenya Morocco Kenya Algeria Kenya Ethiopia Kenya India Kenya Japan Kenya South Korea Kenya China Cenya Thailand Cenya Singapore Cenya United Kingdom Cenya Germany Cenya France Cenya Netherlands Cenya Sweden Cenya Italy Cenya Spain Cenya Poland Cenya Mexico Cenya Brazil Cenya Argentina Cenya Chile Cenya Colombia Cenya United States Cenya Canada Cenya Australia Cenya Uganda Cenya Serbia Cenya	Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
Nigeria Egypt Morocco Morocco Algeria India Ethiopia India India India Japan India South Korea India China India Thailand India Singapore India United Kingdom India Germany India France India Netherlands India Sweden India Italy India Syein India Poland India Mexico India Brazil India Argentina India India	South Africa	<u> </u>	<u> </u>
Egypt	Kenya		
Morocco Algeria Ethiopia India India India Japan India South Korea India China Indiand Thailand Indiand Singapore Indiand United kingdom Indiand Germany Indiand France Indiand Netherlands Indiand Sweden Indiand Italy Indiand Spain Indiand Poland Indiand Mexico Indiand Brazil Indiand Argentina Indiand Chile Indiand Colombia Indiand United States Indiand Canada Indiand Australia Indiand New Zealand Indiand Indiand Indiand Indiand Indiand Indiand Indiand Indiand Indiand Indiand	Nigeria		
Algeria Ethiopia India Japan South Korea China Thailand Singapore United Kingdom Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Egypt	<u> </u>	<u> </u>
Ethiopia	Morocco		
India	Algeria		
Japan South Korea China Thailand Singapore United Kingdom Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Ethiopia		
South Korea Image: China order of the content of the con	India		
China Thailand Singapore United Kingdom Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia United Kingdom Indiversible Individual Indonesia United States Indonesia Vietnam Philippines	Japan		
Thailand Singapore United Kingdom Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia United Kingdom Indeed Singapore	South Korea		
Singapore Inited kingdom Germany Image: Control of the control	China		
United Kingdom Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Thailand		
Germany France Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Pillippines	Singapore		
Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Uniten States Sweden Italy O O O O O O O O O O O O O	United Kingdom		
Netherlands Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Philippines	Germany		
Sweden Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Philippines	France		
Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Netherlands		
Spain Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Sweden		
Poland Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Philippines	Italy		
Mexico Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Spain		
Brazil Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Poland		
Argentina Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Mexico		
Chile Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Brazil	\bigcirc	<u> </u>
Colombia United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Argentina		
United States Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Philippines	Chile	\bigcirc	<u> </u>
Canada Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Colombia		
Australia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	United States		
New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Canada		
Greece O O O O O O O O O O O O O O O O O O	Australia	0	
Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines	New Zealand		
Uganda Serbia Sudi Arabia UAE Syria Indonesia Vietnam Philippines	Greece	<u> </u>	<u> </u>
Serbia O O O O O O O O O O O O O O O O O O O	Rwanda		
Saudi Arabia UAE Syria Indonesia Vietnam Philippines	Uganda		
UAE Syria Indonesia Vietnam Philippines O O O O O O O O O O O O O O O O O O	Serbia	\bigcirc	<u> </u>
Syria	Saudi Arabia	<u> </u>	
Indonesia O O O O O O O O O O O O O O O O O O O		<u> </u>	
Vietnam O O O O O O O O O O O O O O O O O O O	Syria		
Philippines	Indonesia		
Russia			
	Russia		



Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Universal health coverage guarantees access to surgery, chemo, radiotherapy, and targeted therapy.
- Over €100M/year in research funding; high participation in clinical trials and awareness campaigns like "Octobre Rose."

Opportunity

- major cities.
- personalized medicine research outputs in clinical care.

Weakness

- · Regional differences in access speed or pathway navigation.
- Potential disparities between public and private sectors for the newest innovations.

Threats

Increasing cost of

Information gaps in

populations may limit

awareness impact.

could pressure

sustainability.

underserved

innovative treatments

- 5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.
 - 4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.
 - 3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.
 - 2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.
 - 1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	0	<u> </u>	0
Kenya			
Nigeria			
Egypt	0		0
Morocco			0
Algeria			
Ethiopia			
India	0	<u> </u>	<u> </u>
Japan	0		0
South Korea	0		
China	0		<u> </u>
Thailand	0	<u> </u>	<u> </u>
Singapore	0		
United Kingdom	0		
Germany			
France	0		
Netherlands			
Sweden			
Italy	0		
Spain	0		
Poland	0	\bigcirc	<u> </u>
Mexico			
Brazil			
Argentina			
Chile			
Colombia			
United States			
Canada			
Australia	0		
New Zealand	0		0
Greece	0	<u> </u>	<u> </u>
Rwanda			
Uganda			
Serbia	0	<u> </u>	<u> </u>
Saudi Arabia	0		0
UAE	0		0
Syria	0		•
Indonesia	0		0
Vietnam	0	<u> </u>	0
Philippines	0		0
Russia			


W

0

- Expand access to clinical trials beyond
- Further leverage AI and



Survival Rates, Early **Detection** and Palliative Care



Strengths

- 5-year survival rate of ~88%, among the highest in Europe.
- Comprehensive early detection and integrated palliative care systems.

0

Weakness

- Screening participation remains moderate (~47.8%), with room for growth.
- End-of-life care less accessible in rural areas.

- 5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-oflife care.
- 4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

Opportunity

- Boost outreach and participation in national screening campaigns.
- Innovate home-based and communityintegrated palliative care services.

- · Socioeconomic and geographic disparities may undermine outcomes.
- Increasing complexity in patient needs could challenge care coordination.

- 3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.
 - 2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.
 - 1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	<u> </u>	<u> </u>	<u> </u>
Kenya			
Nigeria			
Egypt	<u> </u>	<u> </u>	<u> </u>
Morocco			
Algeria			
Ethiopia			
India		\bigcirc	
Japan			
South Korea			
China		\bigcirc	
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy	0		0
Spain	<u> </u>		<u> </u>
Poland	<u> </u>	<u> </u>	<u> </u>
Mexico		<u> </u>	
Brazil	<u> </u>	<u> </u>	<u> </u>
Argentina	<u> </u>	<u> </u>	<u> </u>
Chile		<u> </u>	<u> </u>
Colombia		<u> </u>	
United States			
Canada			<u> </u>
Australia	<u> </u>		
New Zealand			
Greece	<u> </u>	<u> </u>	<u> </u>
Rwanda			
Uganda			
Serbia			
Saudi Arabia			
UAE			
Syria			
Indonesia	<u> </u>	<u> </u>	
Vietnam	<u> </u>	<u> </u>	
Philippines	<u> </u>	<u> </u>	<u> </u>
Russia			0



0

Utilization of Biomarkers

Strengths

- Universal HER2/ER/PR testing; BRCA testing covered for high-risk patients.
- National reimbursement ensures routine biomarker integration in treatment planning.

Opportunity


- Expand NGS/lipid biopsy use through digital pathology networks.
- Link biomarker testing with real-world data for precision therapy pathways.


Weakness

- Advanced genomic tools like NGS more common in tertiary centers.
- Some rural hospitals may lack routine access to expanded biomarker panels.

- Technological variation across regions may cause care inconsistency
- Capacity limits could delay implementation of complex biomarker tests.

- 5. 80% Biomarker testing is widely available and routinely performed as part of standard clinical practice. Strong integration into treatment decisions, with national coverage and reimbursement ensuring accessibility.
- 4. 61-80%. Biomarker testing is commonly used, but access may be limited in certain regions or patient groups. Some disparities exist in coverage or affordability, but it is still a crucial part of cancer diagnostics
- 3. 41-60% Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.
- 2. 20-40% Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.
- <20% Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.







France I

Clinical Guidelines

Strengths

- Aligned with NCCN/ESMO; updated regularly via INCa.
- Strong clinical adoption supported by multidisciplinary tumor boards.

s w o T

Weakness

- Delay in adoption of new updates in some communitylevel hospitals.
- Complexity of guidelines may be challenging for general practitioners.

Opportunity

- Use national platforms to streamline updates and digital CME.
- Integrate guidelines into EMRs for automated decision support.

- Disparities in training or digital access may slow uniform adoption.
- Delays in harmonizing with fast-changing international standards.



	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	0	*	*	*	*
Feasibility of Integration	*	0	*	×	*
Adoption of International Guidelines	0	*	*	*	*
Engagement with Updates	0	*	*	*	*
ESMO Guidelines Implementation	0	*	*	*	*



France I

0

Reimbursement

Strengths

- National Health Insurance covers all standard treatments and diagnostics.
- ALD system ensures full reimbursement for breast cancer patients.

Opportunity

- Broaden fast-track coverage pathways for targeted therapies.
- Simplify navigation of reimbursement procedures for clinicians.

Weakness

- Access to some novel therapies may face regulatory delays before coverage.
- System complexity can create administrative delays for rare indications.

- High cost of innovation may strain public funding models.
- Budget constraints could delay inclusion of newer molecular tests.



- A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.
- A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as copays, limited coverage, or financial caps on testing.
- No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement	No-cost Access
South Africa	0	*
Kenya	×	×
Nigeria	×	×
Egypt	0	0
Morocco	0	×
Algeria	0	×
Ethiopia	×	×
India	0	×
Japan	0	0
South Korea	0	0
China	0	0
Thailand	0	0
Singapore	0	0
United Kingdom	0	0
Germany	0	0
France	0	0
Netherlands	0	0
Sweden	0	0
Italy	0	0
Spain	0	0
Poland	0	0
Mexico	0	×
Brazil	0	×
Argentina	0	×
Chile	0	0
Colombia	0	×
United States	0	0
Canada	0	0
Australia	0	0
New Zealand	0	0
Greece	0	0
Rwanda	×	×
Uganda	×	×
Serbia	0	0
Saudi Arabia	0	0
UAE	0	0
Syria	0	0
Indonesia	0	0
Vietnam	×	×
Philippines	×	×
Russia	0	0



France I

Breast Cancer Screening

Strengths

- National mammography screening (50-74 yrs) is free and wellestablished.
- High-risk patients eligible for enhanced MRIbased screening.

Weakness

- Screening uptake remains below optimal at ~50%.
- Regional disparities in participation and follow-up rates.

W

S

0

Opportunity

- Strengthen participation through mobile units and personalized outreach.
- Incorporate risk-based screening strategies using genomics and family history.

- Misinformation and health literacy barriers could limit program success.
- Disparities in access and follow-up may erode early detection gains.

Country	Breast Cancer Screening
United States	Biennial mammograms (50-74 years)
United Kingdom	Triennial mammograms (50-71 years)
Canada	Mammograms every 2-3 years (50-74 years)
Australia	Biennial mammograms (50-74 years)
Germany	Mammograms every 2 years (50-69 years)
France	Biennial mammograms (50-74 years)
Netherlands	Mammograms every 2 years (50-75 years)
Sweden	Mammograms every 18-24 months (40- 74 years)
Italy	Mammograms every 2 years (50-69 years)
Spain	Mammograms every 2 years (50-69 years)
Poland	Mammograms every 2 years (50-69 years)
Japan	Mammograms every 2 years (40+ years)
South Korea	Biennial mammograms (40+ years)
China	Regional mammogram programs (40-69 years)
India	Opportunistic screening
Singapore	Biennial mammograms (50-69 years)
Saudi Arabia	Opportunistic screening; regional programs for women aged 40+
UAE	Opportunistic screening; encouraged every 2 years for 40-69 years
Syria	No national program; limited local initiatives due to conflict

Country	Breast Cancer Screening
Thailand	Biennial mammograms (50-69 years)
South Africa	Opportunistic screening
Kenya	No national program
Nigeria	No national program
Egypt	National awareness campaigns
Morocco	National program for 45-69 years
Algeria	Planned national program (50-69 years)
Ethiopia	No national program
Mexico	Biennial mammograms (40-69 years)
Brazil	Biennial mammograms (50-69 years)
Argentina	Biennial mammograms (50-69 years)
Chile	Mammograms every 3 years (50-69 years)
Colombia	Biennial mammograms (50-69 years)
New Zealand	Biennial mammograms (45-69 years)
Greece	Biennial mammograms (50-69 years)
Rwanda	No national program
Uganda	No national program
Serbia	Biennial mammograms (50-69 years)
Indonesia	Opportunistic screening; no national mammography program
Vietnam	Regional mammography programs; pilot programs in urban areas (age 45-69)
Philippines	Opportunistic screening; mammography recommended every 2 years for women 50+
Russia	National program for biennial mammograms (50-69 years)